A citation-based method for searching scientific literature

Jack Ghannam, Laura W Dillon, Christopher S Hourigan. Br J Haematol 2020
Times Cited: 9







List of co-cited articles
136 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K Hills, Christopher S Hourigan,[...]. Blood 2018
390
88

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, François G Kavelaars, Adil Al Hinai, Annelieke Zeilemaker, Claudia A J Erpelinck-Verschueren, Patrycja L Gradowska, Rosa Meijer, Jacqueline Cloos,[...]. N Engl J Med 2018
299
88

Assessment of Minimal Residual Disease in Standard-Risk AML.
Adam Ivey, Robert K Hills, Michael A Simpson, Jelena V Jovanovic, Amanda Gilkes, Angela Grech, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason,[...]. N Engl J Med 2016
395
77

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson,[...]. Blood 2017
66

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Christopher S Hourigan, Laura W Dillon, Gege Gui, Brent R Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, Abel Licon, Edwin P Alyea, Asad Bashey,[...]. J Clin Oncol 2020
79
66

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Frank G Rücker, Mridul Agrawal, Andrea Corbacioglu, Daniela Weber, Silke Kapp-Schwoerer, Verena I Gaidzik, Nikolaus Jahn, Thomas Schroeder, Mohammed Wattad, Michael Lübbert,[...]. Blood 2019
27
66

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Marie Balsat, Aline Renneville, Xavier Thomas, Stéphane de Botton, Denis Caillot, Alice Marceau, Emilie Lemasle, Jean-Pierre Marolleau, Olivier Nibourel, Céline Berthon,[...]. J Clin Oncol 2017
128
55

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Sylvie D Freeman, Robert K Hills, Paul Virgo, Naeem Khan, Steve Couzens, Richard Dillon, Amanda Gilkes, Laura Upton, Ove Juul Nielsen, James D Cavenagh,[...]. J Clin Oncol 2018
78
55

Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Richard Dillon, Robert Hills, Sylvie Freeman, Nicola Potter, Jelena Jovanovic, Adam Ivey, Anju Shankar Kanda, Manohursingh Runglall, Nicola Foot, Mikel Valganon,[...]. Blood 2020
31
55

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, Regina Herbst, Dominik Wolf, Claudia D Baldus, Uta Oelschlägel, Anke Mütherig, Lars Fransecky, Richard Noppeney,[...]. Lancet Oncol 2018
101
55

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
Yu Wang, De-Pei Wu, Qi-Fa Liu, Ya-Zhen Qin, Jing-Bo Wang, Lan-Ping Xu, Yan-Rong Liu, Hong-Hu Zhu, Jia Chen, Min Dai,[...]. Blood 2014
69
55

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki, Brent L Wood, Megan Othus, Jerald P Radich, Anna B Halpern, Yi Zhou, Marco Mielcarek, Elihu H Estey, Frederick R Appelbaum, Roland B Walter. J Clin Oncol 2016
235
44


GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Adriano Venditti, Alfonso Piciocchi, Anna Candoni, Lorella Melillo, Valeria Calafiore, Roberto Cairoli, Paolo de Fabritiis, Gabriella Storti, Prassede Salutari, Francesco Lanza,[...]. Blood 2019
45
44

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Monique Terwijn, Wim L J van Putten, Angèle Kelder, Vincent H J van der Velden, Rik A Brooimans, Thomas Pabst, Johan Maertens, Nancy Boeckx, Georgine E de Greef, Peter J M Valk,[...]. J Clin Oncol 2013
281
44

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
Hong-Hu Zhu, Xiao-Hui Zhang, Ya-Zhen Qin, Dai-Hong Liu, Hao Jiang, Huan Chen, Qian Jiang, Lan-Ping Xu, Jin Lu, Wei Han,[...]. Blood 2013
191
44

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016
44

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Ing S Tiong, Richard Dillon, Adam Ivey, Tse-Chieh Teh, Phillip Nguyen, Nicholas Cummings, David C Taussig, Annie-Louise Latif, Nicola E Potter, Manohursingh Runglall,[...]. Br J Haematol 2021
12
44

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Robert Puckrin, Eshetu G Atenafu, Jaime O Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C Shuh, Karen Yee,[...]. Haematologica 2021
6
66

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Eric Jourdan, Nicolas Boissel, Sylvie Chevret, Eric Delabesse, Aline Renneville, Pascale Cornillet, Odile Blanchet, Jean-Michel Cayuela, Christian Recher, Emmanuel Raffoux,[...]. Blood 2013
218
44

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
Nona Shayegi, Michael Kramer, Martin Bornhäuser, Markus Schaich, Johannes Schetelig, Uwe Platzbecker, Christoph Röllig, Caroline Heiderich, Olfert Landt, Gerhard Ehninger,[...]. Blood 2013
125
44

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Y Zhou, M Othus, D Araki, B L Wood, J P Radich, A B Halpern, M Mielcarek, E H Estey, F R Appelbaum, R B Walter. Leukemia 2016
95
33

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
Wendelien Zeijlemaker, Tim Grob, Rosa Meijer, Diana Hanekamp, Angèle Kelder, Jannemieke C Carbaat-Ham, Yvonne J M Oussoren-Brockhoff, Alexander N Snel, Dennis Veldhuizen, Willemijn J Scholten,[...]. Leukemia 2019
55
33

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
Sylvie D Freeman, Paul Virgo, Steve Couzens, David Grimwade, Nigel Russell, Robert K Hills, Alan K Burnett. J Clin Oncol 2013
200
33

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop,[...]. Blood 2018
103
33

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Bartlomiej M Getta, Sean M Devlin, Ross L Levine, Maria E Arcila, Abhinita S Mohanty, Ahmet Zehir, Martin S Tallman, Sergio A Giralt, Mikhail Roshal. Biol Blood Marrow Transplant 2017
74
33

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Alex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, Francesca Guijarro, Ana Garrido, Susana Vives, Mar Tormo, Montserrat Arnan, Olga Salamero, Antònia Sampol,[...]. Br J Haematol 2020
8
37

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, Thomas W Prior, Konstanze Döhner, Guido Marcucci,[...]. N Engl J Med 2017
821
33

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.
Alan K Burnett, Anthony Goldstone, Robert K Hills, Donald Milligan, Archie Prentice, John Yin, Keith Wheatley, Ann Hunter, Nigel Russell. J Clin Oncol 2013
131
33

Reduced mortality after allogeneic hematopoietic-cell transplantation.
Ted A Gooley, Jason W Chien, Steven A Pergam, Sangeeta Hingorani, Mohamed L Sorror, Michael Boeckh, Paul J Martin, Brenda M Sandmaier, Kieren A Marr, Frederick R Appelbaum,[...]. N Engl J Med 2010
927
33

MRD evaluation of AML in clinical practice: are we there yet?
Sylvie D Freeman, Christopher S Hourigan. Hematology Am Soc Hematol Educ Program 2019
13
33

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.
Sarah A Buckley, Brent L Wood, Megan Othus, Christopher S Hourigan, Celalettin Ustun, Michael A Linden, Todd E DeFor, Michele Malagola, Chloe Anthias, Veronika Valkova,[...]. Haematologica 2017
109
33

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Bart L Scott, Marcelo C Pasquini, Brent R Logan, Juan Wu, Steven M Devine, David L Porter, Richard T Maziarz, Erica D Warlick, Hugo F Fernandez, Edwin P Alyea,[...]. J Clin Oncol 2017
282
33

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Charles Craddock, Aimee Jackson, Justin Loke, Shamyla Siddique, Andrea Hodgkinson, John Mason, Georgia Andrew, Sandeep Nagra, Ram Malladi, Andrew Peniket,[...]. J Clin Oncol 2021
9
33

Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Richard D Press, Garrett Eickelberg, Allison Froman, Fei Yang, Alex Stentz, Ellen M Flatley, Guang Fan, Jeong Y Lim, Gabrielle Meyers, Richard T Maziarz,[...]. Am J Hematol 2019
26
22

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Christophe Willekens, Odile Blanchet, Aline Renneville, Pascale Cornillet-Lefebvre, Cécile Pautas, Romain Guieze, Norbert Ifrah, Hervé Dombret, Eric Jourdan, Claude Preudhomme,[...]. Haematologica 2016
61
22

Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance.
Jing-Ni Sui, Qiu-Sheng Chen, Yun-Xiang Zhang, Yan Sheng, Jing Wu, Jun-Min Li, Xiang-Qin Weng, Bing Chen. Am J Hematol 2019
7
28

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.
Giacomo Gianfaldoni, Francesco Mannelli, Tamara Intermesoli, Sara Bencini, Damiano Giupponi, Giorgio Farina, Ilaria Cutini, Maria Ida Bonetti, Arianna Masciulli, Ernesta Audisio,[...]. Blood Adv 2020
6
33

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.
Thomas Prebet, Sarah Bertoli, Jacques Delaunay, Arnaud Pigneux, Eric Delabesse, Marie Joelle Mozziconacci, Audrey Bidet, Christian Recher, Norbert Vey. Haematologica 2014
21
22

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Jacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, Angele Kelder, F Huang, Gerrit Sijm, Maike Vonk, Alexander N Snel, Jennifer R Scheick, Willemijn J Scholten,[...]. J Vis Exp 2018
16
22

Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Luca Maurillo, Francesco Buccisano, Alessandra Spagnoli, Giovanni Del Poeta, Paola Panetta, Benedetta Neri, Maria Ilaria Del Principe, Carla Mazzone, Maria Irno Consalvo, Anna Tamburini,[...]. Haematologica 2007
55
22

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Paola Minetto, Fabio Guolo, Marino Clavio, Annalisa Kunkl, Nicoletta Colombo, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, Daniela Guardo, Filippo Ballerini,[...]. Br J Haematol 2019
7
28

Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR.
N Boeckx, J De Roover, V H J van der Velden, J Maertens, A Uyttebroeck, P Vandenberghe, J J M van Dongen. Leukemia 2005
11
22

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Wendelien Zeijlemaker, Angele Kelder, Jacqueline Cloos, Gerrit Jan Schuurhuis. Curr Protoc Cytom 2019
6
33

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, Y Alvarado, N Pemmaraju, P Bose, K Naqvi,[...]. Leukemia 2018
25
22

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Susanne Schnittger, Wolfgang Kern, Claudia Tschulik, Tamara Weiss, Frank Dicker, Brunangelo Falini, Claudia Haferlach, Torsten Haferlach. Blood 2009
229
22

Can we incorporate MRD assessment into clinical practice in AML?
Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, Jacqueline Cloos. Best Pract Res Clin Haematol 2019
10
22

Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.
Diana Hanekamp, Costa Bachas, Arjan van de Loosdrecht, Gert Ossenkoppele, Jacqueline Cloos. Pathology 2020
3
66

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Mithun Vinod Shah, Jeffrey L Jorgensen, Rima M Saliba, Sa A Wang, Amin M Alousi, Borje S Andersson, Qaiser Bashir, Stefan O Ciurea, Partow Kebriaei, David Marin,[...]. Biol Blood Marrow Transplant 2018
34
22



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.